Introduction
Philadelphia, PA, USA Ulcerative colitis (UC) is a form of chronic idiopathic inflam- 3 Present address: Second Department of Surgery, Fukuoka University matory bowel disease (IBD) that usually has a course of School of Medicine, Fukuoka, Japan intermittent exacerbation and remission, and less commonly 4 To whom correspondence should be addressed an unremitting course or a course of only a single attack. (1) Email: hs_cooper@fccc.edu
One of the complications of UC is an increased risk for the Animal models of colitis, which develop dysplasia and development of cancer of the colon and rectum. The cumulative cancer similar to human ulcerative colitis are needed to risk for developing cancer in patients with longstanding pancolfurther investigate the dysplasia cancer sequence. This itis is~10-13% at 25 years of disease (2) (3) (4) (5) . In most instances study describes the expression of B-catenin and p53 along cancer evolves through a neoplastic process called dysplasia with the histopathology and inflammation scores as they (2) (3) (4) (5) (6) (7) (8) (9) . relate to dysplasia and cancer in the dextran sulfate sodium
There are many animal models for IBD, but only a few of (DSS) colitis model. Swiss Webster mice were fed with 5% these models are applicable to study the dysplasia-cancer DSS as follows: group A, four cycles of DSS, 84 days total sequence. These animal models can be characterized as spon-(1 cycle ⍧ 7 days DSS ⍣ 14 days H 2 O); group B, four taneous, genetically engineered, and those induced by exogencycles DSS followed by 120 days H 2 
O, 204 days total; ous agents (10-22). Cotton top tamarins (Saguinus oedipus) group C, 7 days DSS followed by 180 days H 2 O, 187 days
are New World monkeys that develop colitis and cancer when total; group D, 7 days DSS followed by 90 days H 2 O, 97 in confinement. However, unlike in the human, these cancers days total. The incidences of dysplasia and/or cancer were tend to arise unassociated with dysplasia and it can take up to 15.8, 37.5, 18.1 and 0% in groups A-D, respectively. 4 years to develop cancers. The expensive nature of procuring Dysplasia and/or cancer occurred as flat lesions or as and housing these endangered species precludes using this dysplasia-associated lesion or mass (DALM) as observed in model in all laboratories (10-12). Recently, interleukin-10 the human. Thirty-three percent of cancers had associated knockout and Gα 1 knockout (deficient) mice have been dysplasia. Within group A, inflammation scores were signishown to develop colitis-associated adenocarcinoma (13,14). ficantly higher in animals with dysplasia and/or cancer However, these models have not been fully characterized for compared with those without dysplasia and/or cancer cancer studies as they relate to the human. In recent years, a (P < 0.05-P < 0.0001). Inflammation scores were significfew investigators have described the appearance of dysplasia antly higher in animals with cancers versus those with and/or cancers in mice, rats and hamsters when they are fed dysplasia (P < 0.015) and in flat dysplasia and/or cancer dextran sulfate sodium (DSS) (15-22). However, none of versus DALM (P < 0.0042). B-catenin showed translocation these studies has examined the incidence, distribution and from the cell membrane to the cytoplasm and/or nucleus multifocality of dysplasia and the association of colitis with in 100% of DALM and 5.8% of flat dysplasia and/or dysplasia and cancer. Furthermore, none of these studies has cancer. A total of 94.2% of flat dysplasia and/or cancer correlated the clinical severity of disease, the role of single had exclusive cell membrane expression compared with versus multiple attacks of colitis, the role of inflammation and 0% DALM (P < 0.0001). Only 7.4% of dysplasia and/ the effect of disease inactivity in the development of dysplasia or cancer showed nuclear expression of p53. In colitisand cancer. associated dysplasia and/or cancer in the DSS model: (i)
In human UC-associated neoplasia, p53 mutation or overhistology resembles that in the human; (ii) inflammation expression is reported to occur commonly as an early event plays a significant role in the dysplasia cancer sequence in the dysplasia cancer sequence (23-32). However, in sporadic and whether dysplasia and/or cancer grows as a flat lesion colon cancer, it is a late event in the adenoma cancer sequence or a DALM; (iii) the early molecular pathways are different (23-25,27-29,32). There are only two reported studies that for flat dysplasia and/or cancer versus DALM, with nuclear/ have looked at the role of p53 in animal models of colitiscytoplasmic translocation of B-catenin as an early event in associated neoplasia, one of these studies is reported in abstract DALM but not flat dysplasia and/or cancer; and (iv) p53
form (33) and the other study reported only three cases (34) . has little or no role in dysplasia and/or cancer. This
These studies have reported different results. The former study well characterized model provides an excellent vehicle for reported that p53-deficient mice with chronic DSS colitis had studying the roles of inflammation, the molecular events significantly higher numbers of dysplastic lesions than control mice with DSS colitis (33) . The latter study reporting a
Abbreviations: DAI, disease activity index; DALM, dysplasia-associated 0% incidence of p53 mutations in colitis-induced rat colon lesion or mass; DSS, dextran sulfate sodium; IBD, inflammatory bowel disease; UC, ulcerative colitis.
cancers (34) .
Controls (groups E and F) were mice of similar sex and age (100-and 200-dayold mice, respectively) that drank regular H 2 O. Animals were killed by an 
Materials and methods

The evaluation of B-catenin and p53 Animals
Both B-catenin and p53 were evaluated by immunohistochemistry. The antibody Female, 8-week-old Swiss Webster mice (FBR-Taconic) weighing 25-30 g were for B-catenin was purchased from Sigma (St Louis, MO). This is a rabbit used in this study. The animals were housed in a vivarium with controlled polyclonal antibody raised against B-catenin peptide amino acids 768-781. The temperature at 23°C and light and dark cycles. Mice were fed standard mice p53 antibody, product cm-1 (Signet Laboratories, Dedham, MA), is a rabbit chow pellets and had access to drinking tap water supplied in bottles. Animals polyclonal that reacts with both wild-type and mutant p53. The B-catenin antiwith pain and distress were treated when necessary with buprenorphine or killed.
body was used at a dilution of 1:4000 and 1:8000 and the p53 antibody was used This animal protocol was approved by the Institutional Animal Care and Use at a dilution of 1:80. Heat epitope retrieval in a citrate buffer in a vegetable Committee, MCP Hahneman University.
steamer was used. An automated Techmate 1000 was used for immunohisto-
Study design (induction of colitis)
chemistry as per standard protocol with the exception that biotinylated sheep The design for inducing colitis-associated dysplasia/cancer is shown in Table I. anti-rabbit (Vector labs) was substituted for the Techmate standard secondary Colitis was induced by feeding ad libitum 5% DSS, molecular weight antibody. A mouse benzo[a]pyrene-induced skin squamous cell carcinoma, 30-40 000 (ICN, Costa Mesa, CA) in the drinking water. The DSS solution was which is known to express mutant p53 (45, 46) and human colorectal adenocarcinnot sterilized; however, the solutions were changed daily. The groups were oma were used as positive controls for the p53 antibody. Staining for p53 was divided into groups A-F. Group A animals were exposed to four cycles of DSS considered positive if: (i) the intensity of nuclear staining was equal or greater (the basic cycle is 7 days of DSS followed by 14 days of H 2 O). Group A was to that of the mouse skin cancers and (ii) if Ͼ10% of cells were positive. Previous subdivided into groups A 1 , A 2 and A 3 . The intent was to modify the clinical studies have shown that Ͼ10% positive nuclear staining correlates with the severity of disease to see if clinical severity of disease correlated with dysplasia presence of mutated p53 (26,47). Controls for B-catenin expression were normal and/or cancer. The disease activity index (DAI; see below) is a measurement of colon and colonic adenocarcinoma (human) and normal and neoplastic colonic clinical disease severity (activity) with scores ranging from 0 to 3 with 3 being lesions from mice possessing a germline mutation in the APC gene (Min). the most severe. The DAIs for groups A 1 , A 2 and A 3 were maintained at 3.0, 2.0
Non-immune rabbit IgG of similar protein concentrations were substituted for and 1.5, respectively. To maintain a DAI of 1.5-2.0, the basic cycle was modified B-catenin and p53 as negative controls. to 4-5 days of DSS feeding. Mice in group B were fed DSS for four cycles and killed 120 days after the end of the fourth cycle (204 days total). The intent here
Statistical methods was to see the effect of inactive colitis on progression of dysplasia to cancer and All values are expressed as the mean Ϯ SE. Comparisons were done using onethe effect of longevity of disease in developing dysplasia and/or cancer. Group way ANOVA followed by Dunnet's test. Univariate linear regression analysis C was fed DSS for 7 days followed by 180 days of H 2 O (187 days total) and of multiple squares was done to draw conclusions where appropriate. Odds group D was fed DSS for 7 days followed by 90 days of H 2 O (97 days total). ratios were done using 2ϫ2 contingency tables followed by determining 95% The intent of groups C and D was to see if a single attack of colitis was sufficient to induce dysplasia and/or cancer and its relationship to longevity of disease.
confidence intervals (95%CI). 
A 1 , four cycles DSS, 84 days total, DAI ϭ 3.0; A 2 , four cycles DSS, 84 days total, DAI ϭ 2.0; A 3 , four cycles DSS, 84 days total, DAI ϭ 1.5; B, four cycles DSS followed by 120 days H 2 O, 204 days total; C, 7 days DSS followed by 180 days H 2 O, 187 days total; D, 7 days DSS followed by 90 days H 2 O, 97 days total; E, age-and sex-matched non-DSS fed, 100 days total; F, age-and sex-matched non-DSS fed, 200 days total. The data regarding incidence of indefinite for dysplasia, dysplasia and cancer, are presented in by 90 days H 2 O; 97 days total) was 37.5, 18.1 and 0%, respectively. The incidence of dysplasia and/or cancer in control animals (groups E and F) was 0%. The incidence of dysplasia was 9.7, 31.2, 18.1 and 0% in groups A-D, respectively, while the incidence of cancer was 9.7, 25, 0 and 0% in groups A-D, respectively. Despite differences in DAI between groups A 1 , A 2 and A 3 , there was no statistically significant difference between these groups regarding the incidence of dysplasia and/or cancer. Similarly there was no statistically significant difference between groups A, B and C. Among all the animals with dysplasia and/or cancer the incidence of dysplasia and/or cancer was 20, 44 and 36% in the proximal, middle and distal colon segments, respectively. In general, inflammation was most severe in the middle and distal segments, but this was not statistically significant for all groups. Eighteen of 21 (87.5%) animals with dysplasia and/or cancer had lesions limited to only one colon segment, one the four cycle groups with different DAI the inflammation animal (4.7%) had lesions in two different segments and two scores in groups A 1 (DAI 3.0), A 2 (DAI 2.0) and A 3 (DAI animals (9.5%) had lesions in all three segments. Of the 12 1.5) were 71.7 Ϯ 11.4, 24.4 Ϯ 12.5 and 26.8 Ϯ 7.3, respectively. animals with cancer, only two (16.6%) had two or more
Results
The inflammation scores in group A 1 were statistically signisynchronous cancers. ficantly higher than groups A 2 and A 3 (P Ͻ 0.012). The Dysplasia/cancer relationships inflammation scores correlated with the DAI (r ϭ 0.95, P Ͻ 0.01). In groups A 1 , A 2 and A 3 , those animals with Ten of 15 (66.6%) cancers arose in colons without associated dysplasia while only 33.3% (five of 15) cancers arose in colons dysplasia and/or cancer had significantly higher inflammation scores than those without dysplasia and/or cancer ( Figure 1 ). with associated dysplasia. Of the five cancers with associated dysplasia, three (60%) actually arose out of dysplasia (two In contrast, inflammation scores in groups B, C and D did not correlate with the appearance of dysplasia and/or cancer. from DALM and one from flat dysplasia), one (20%) had dysplasia in the same segment of the colon and one (20%)
Combining all the groups together, the mean inflammation score for animals with cancer was 129 Ϯ 38 compared with had dysplasia in a different segment of the colon to the actual cancer.
21.0 Ϯ 5.5 for those animals with dysplasia; this difference was significant (P Ͻ 0.015) (Figure 2) .
Inflammation, scores, ulcer scores and DAI
Extended studies The inflammation scores for all groups are shown in Table III . There was no significant relationship between ulcer scores and
The incidence of dysplasia and/or cancer in group B (four cycles DSS followed by 120 days of H 2 O) was 37.5% compared dysplasia and/or cancer in any of the groups studied. Comparing submucosa. These cancers consisted of well-differentiated with 15.8% in the combined four cycle group (A 1 , A 2 and A 3 ). These differences show a major trend towards an increased glands ( Figure 6 ). DALMs with invasive cancer were seen only in the group receiving four cycles of DSS followed by incidence of dysplasia and/or cancer with longevity of disease between groups with identical initial insult, even in the setting 120 days H 2 O (group B). The flat cancers consisted of malignant glands dropping off from the bottom of the crypts of colitis in clinical remission. The incidence of dysplasia and/ or cancer in group C (7 days DSS followed by 180 days H 2 O) and invading into muscularis mucosae or into the submucosa and beyond, often eliciting a desmoplastic reaction. These was 18.1% compared with 0% in group D (7 days DSS followed by 90 days H 2 O). Groups C and D show that a single invasive cancers were often associated with adjacent or overlying ulceration. Cytologically, these invasive glands showed attack of colitis is sufficient to induce dysplasia; however, dysplasia will develop only after longstanding disease (group loss of mucin production with vesicular nuclei, prominent nucleoli and central lumenal necrosis; however, others were C versus D). Groups B and C allow us to compare the incidence of dysplasia and/or cancer as it relates to multiple extremely well differentiated ( Figure 7 ). This pattern of cancers dropping off from the bottom of the crypts is quite reminiscent attacks of colitis versus a single attack among animals with longstanding colitis of approximately similar duration. The of cancers arising in human IBD (48) . The majority of cancers were of the early invasive type. Mucinous-type carcinoma incidence of dysplasia and/or cancer was 37.5% in group B (multiple attacks of colitis) compared with 18.1% in group C similar to that seen in human UC-related cancer was also present (48) . (single attack of colitis).
The histological changes considered indefinite for dysplasia Pathology (see Materials and methods) were for the most part reactive Gross lesions were noted in only four animals (three in group and/or regenerative atypia associated with overlying or adjacent B and one in group C). These lesions were dome shaped and erosion or ulceration or less commonly two to three isolated polypoid and ranged in size from 3 to 6 mm. crypts with decreased mucin production but with maturation The dysplastic and cancer lesions could be divided into two towards the surface. major types, flat and elevated (polypoid); the latter were similar B-catenin expression (Table IV ) to the DALM seen in the human. Ten of 15 (67%) dysplastic lesions were DALMs and five of 15 (33%) dysplastic lesions Thirteen cancers, 14 dysplasias, 15 indefinite for dysplasia, 15 negative for dysplasia and 10 control animals were studied for were flat. Two of 15 (16.5%) cancers arose within a DALM and 13 of 15 (83.4%) cancers were flat. The odds ratio of B-catenin expression. Of the 13 cancers, 12 were flat and one arose in a DALM, and of the 14 dysplasias, five were flat and cancer arising within a DALM is low at 0.08 (95%CI 0.012-0.48) while the odds ratio of cancer arising within a flat lesion nine were DALMs. In controls, B-catenin was expressed exclusively on the cell membrane ( Figure 8 ). All 10 DALMs is high at 13 (95%CI 2.07-81.52). The inflammation scores for the group of dysplasia and/or cancer lesions of the DALM (100%) showed translocation of B-catenin to the cytoplasm and/or nucleus ( Figure 9 ). Within each DALM the percentage type was significantly lower than for those of the flat lesions (18.2 Ϯ 3.4 versus 183.7 Ϯ 47.6; P Ͻ 0.0042) (Figure 3) . of neoplastic cells showing cytoplasmic and/or nuclear expression of B-catenin ranged from 5 to 75% (mean 35%). Within Histologically, DALMs showed proliferation of glands resulting in the formation of a polypoid mass. Architecturally, the same group of neoplastic cells one could see cells with retained membrane expression adjacent to, or admixed with there was tubule formation, some with irregularity and cribriforming of glands. Cytologically, mucin production was often cells showing cytoplasmic and/or nuclear expression of B-catenin (Figure 10 ). The mean percentage of cells with reduced and the nuclei were vesicular with nucleoli or elongated, hyperchromatic, and stratified to the surface of the cell cytoplasmic and/or nuclear expression was 42.6% for highgrade dysplasia and 21% for low-grade dysplasia. While (Figure 4) . Foci of intraglandular necrosis could occasionally be identified. The flat dysplasias consisted of as little as three showing a trend, this was not statistically significant (P ϭ 0.08). The mean percentage of cells with cytoplasmic and/or to four glands to diffuse areas. These flat lesions showed the same architectural and cytological changes as seen in the nuclear expression was 30.25% in 84 day animals versus 48.25% in 204 day animals. Sixteen of 17 (94.2%) flat DALMs ( Figure 5 ). Five dysplasias were categorized as low grade dysplasia and 10 dysplasias were categorized as high dysplasia/cancer lesions showed exclusively cell membrane expression of B-catenin ( Figure 11 ) and one of 17 (5.8%) flat grade dysplasia.
The cancers that arose within DALMs consisted of glands lesions showed cytoplasmic and/or nuclear expression of B-catenin. (This latter lesion was difficult to differentiate that invaded into the muscularis mucosae and/or into the between a flat lesion or an early DALM.) The odds ratio two of 27 (7.4%) dysplastic and/or cancer lesions (Figure 12 ). P53 expression was not seen in any of the cancers. for cytoplasmic and/or nuclear translocation of B-catenin in DALMs versus exclusive cell membrane expression in flat lesions was 1250 (95%CI 0.001-0068) and the Fisher's exact Discussion two-tailed was P Ͻ 0.0001. All cases indefinite for dysplasia
The focus of this study was to characterize the molecular events, and negative for dysplasia showed an exclusive cell membrane histopathology and role of inflammation in the development of pattern; however, all indefinite and negative lesions were from dysplasia and/or cancer in the DSS model of mouse colitis flat mucosa.
and to draw analogy to UC-associated dysplasia and/or cancer p53 Expression in the human with the intent to use this model for further molecular and chemopreventive research. Our findings show Control animals (n ϭ 10), animals negative for dysplasia (n ϭ 15), and animals indefinite for dysplasia (n ϭ 15) all failed to that our model and the human are similar regarding histopathology, the incidence of dysplasia and/or cancer and the increasing show nuclear expression for p53. Nuclear expression of p53 was present in one DALM (dysplasia) and one flat dysplasia incidence of dysplasia and/or cancer with longevity of disease. Our model and the human are dissimilar regarding the role of lesion. Overall nuclear expression of p53 was present in only In various studies of human patients with universal longstanding UC, the incidence of dysplasia has ranged from 7.5 to 38% with a mean of~15% (3-5,49-50) and the cumulative risk for cancer is reported at 7-12% at 20 years of disease (2-5,9,49,51). Although we realize that results will vary with the dosage and longevity of DSS treatment, our results are similar to those of dysplasia and cancer reported in human studies. The cumulative risk for dysplasia and cancer increases with length of disease with the former reported at 10.0% at 17 years, 14.2% at 25 years and 32.8% at 30 years (5) and similar, as the incidence of dysplasia was approximately three times higher in those animals that were killed 120 days after four cycles (group B, 31%) versus those that were killed after identical to that seen in humans. The types of cancers seen in our animals are histologically identical to that seen in humans with chronic UC, namely cancers arising in flat mucosa with p53, multifocality of disease and a different incidence of dysplasia-associated cancer. We were unable to draw a statista dropping off or invasion from the bottom of the crypts, mucinous cancers and cancers arising out of DALMs (48) . ical conclusion regarding disease activity and dysplasia and/ or cancer. Finally, we describe new and novel findings regarding
In human UC, dysplasia is found in two or more segments in 42-75% of the cases and the incidence of multiple synchronous the role of B-catenin in the early molecular pathway of DALM and/or cancer is not related to the clinical disease activity (54,55). In order to validate this finding, we designed studies that involved regulating the disease activity between groups A 1 (DAI 3.0), A 2 (DAI 2.0) and A 3 (DAI 1.5). Whereas the data showed an increased incidence of dysplasia or dysplasia and/or cancer in group A 1 (DAI 3.0), we believe that because of the sample size and a possible type II error, it is difficult to draw any conclusion on the association between disease activity and the incidence of dysplasia or dysplasia and/or cancer in this model. Interestingly, in humans (54,55), the incidence of dysplasia and cancer is not related to the severity of clinical activity.
Inflammation can lead to carcinogenesis through pathways of free radicals which can lead to damage to DNA, lipids and protein. This in a background of increased proliferation can lead to fixation of mutations (56-65). In chronic human UC there are no known studies that have looked at histopathological levels of inflammation as it relates to dysplasia and/or cancer. In fact, many dysplasias and cancers arise on a background of inactive colitis. In this study we showed that within each group High power view showing strong nuclear and cytoplasmic staining.
receiving four cycles of DSS and of identical DAI (group A 1 , A 2 and A 3 ), those animals with dysplasia and/or cancer had significantly higher inflammation scores than those without dysplasia and/or cancer. Recent studies of cotton top tamarins cancers is reported to vary from 22 to 50% (6) (7) (8) 52, 53) . In contrast to human UC, our study showed that dysplasia was (11,12) have shown that those animals which developed colitisassociated cancer had higher inflammation scores than those present in two or more segments in only 14.2% of the animals and the incidence of synchronous cancers was only 15%. without cancer. However, among animals (group B) receiving four cycles of DSS followed by 120 days of H 2 O (204 days Most large studies report that 75% of cancers that arise in human chronic UC, do so in association with dysplasia (6-8).
total) there was no significant difference in inflammation scores between those animals with dysplasia and/or cancer than those In our study, only 33% of cancers arose in colons with associated dysplasia indicating that in our model cancers without dysplasia and/or cancer. This might be expected since colitis was resolving as the last insult with DSS occurred 120 do arise in association with dysplasia, although~50% less frequently than in the human.
days prior to killing. However, in this group there was progression of DALMs to invasive cancer and a higher It is generally believed that the development of dysplasia important factor in the development of dysplasia and/or cancer. Analogus to our model this might explain why, in human UC, one frequently finds dysplasia and/or cancer on a background of inactive colitis.
In this study we found statistically significant higher inflammation scores in flat versus DALM lesions and in animals with cancers versus those with dysplasia. However, this latter finding might be interrelated to the flat versus DALM type of lesions as the odds ratio of cancer arising within a DALM is at 0.08 but the odds ratio of cancer arising within a flat lesion is 13.
The number of attacks of colitis may also play a role in the length of time needed to develop dysplasia and/or cancer. We were able to induce a 15.8% incidence of dysplasia and/or cancer after 84 days in those animals given four cycles of DSS (group A); however, we could not induce dysplasia and/ or cancer after 97 days in the group of animals (group D) treated with DSS for only 7 days followed by 90 days of H 2 O. Interestingly, in this model a single episode of colitis also resulted in the development of dysplasia albeit after a prolonged period. Sequential killing of mice after a single attack of colitis showed that at 90 days none of the mice had developed dysplasia or cancer. However, after 180 days, 18% of mice had developed dysplasia, but not cancer, suggesting that a single attack of colitis was sufficient for some mice to develop dysplasia. Whether this phenomenon is true in humans is not clear.
B-catenin is a 92 kDa protein that has a high sequence similarity to the polarity gene Armadillo in Drosophila (35). In both the human and Drosophila, B-catenin plays a role in cell-cell adhesion and is involved in intracellular signaling (36) . Wild-type APC is responsible for homeostatic control of degradation of B-catenin. With loss of APC function, B-catenin accumulates in the cytoplasm and nucleus and activates Tcf4 and c-myc. In the human, sporadic (non-colitic) colorectal adenomas and carcinomas show translocation of B-catenin from the cell membrane to the cytoplasm/nucleus, which, along with loss of APC function, is believed to be an early event in the development of colorectal neoplasia (37) (38) (39) (40) . This translocation has been shown to be associated with loss of function of APC; however, it has been shown that 48% of human colorectal adenoma/cancers lacking mutation of APC were found to have mutations of the B-catenin gene (67). In rats, cytoplasmic/nuclear translocation of B-catenin has been reported in azoxymethane-induced adenomas and carcinomas; however, in this model loss of APC function is rare (42) . Rat colon tumors induced by methylazoxymethanol acetate and gene in the absence of APC mutation (43) . Karayiannakis et al. (68) studied the expression of B-catenin in humans with UC and Crohn's disease. They found that in inactive or active colitis, B-catenin was always localized to the cell membrane; incidence of dysplasia and/or cancer (37%) compared with animals (15.8%) receiving only four cycles of DSS (84 days).
however, they did not study dysplastic or cancerous lesions.
To date the only study of B-catenin in UC-associated neoplasia Wilcox et al. (66) fed rats poligenan, a non-genotoxic, low molecular weight sulfated polysaccharide. They showed that reported loss of heterozygosity of B-catenin in 7% of human UC-related cancers compared with 31% sporadic cancers. animals fed polignenan had significantly increased cellular proliferation as measured by proliferating cell nuclear antigen However, they did not study B-catenin immunohistochemically (32) . In our study, we found translocation of B-catenin to the and thymidine kinase activity. After stopping the poligenan diet, the increased levels of cellular proliferation continued cytoplasm/nucleus in 100% of DALMs; however, 94.2% of flat dysplasia and/or cancers exclusively expressed B-catenin with some labeling still at the surface. These findings might indicate that high levels of inflammation could be an important on the cell membrane (P Ͻ 0.0001). Our findings suggest that translocation of B-catenin is involved in polypoid dysplasia/ factor in the earlier stages of initiation of dysplasia while in longstanding colitis, continued inflammation may not be an cancer rather than flat lesions. This difference between flat expression of p53 was seen in 0% of cancers and in only 2/14 dysplasias (14.2%). The frequency of p53 alterations in data indicating the existence of pathways of colorectal carcinogenesis independent of both APC and B-catenin. In our study murine primary epithelial tumors is generally lower than that seen in the human (72). Carcinogen-induced tumorigenesis of we do not know whether the translocation of B-catenin was due to loss of APC function or directly through a mutation of colorectal cancer in both mice and rats has resulted in conflicting reports regarding molecular alterations and nuclear B-catenin itself. In our study, the mean percentage of cells with cytoplasmic and/or nuclear expression of B-catenin was expression of p53 with some authors reporting no role for p53 while others report a role for p53 (73-77). Studies of mice 42.6% for high-grade dysplasia versus 21% for low-grade dysplasia and 30.3% in 84 day animals versus 48.3% in 204 heterozygous for p53 show a 2-3% incidence of spontaneous colon cancers (78,79); however, colon cancers are not reported day animals. Hao et al. (40) showed that both carcinomas and adenomas with high grade dysplasia had a significantly greater in mice homozygous deficient for p53 (80). Min mice crossed with p53-deficient mice (p53 -/-) do not show an increased percentage of lesions showing cytoplasmic/nuclear expression of B-catenin than did adenoma with low-grade dysplasia. number of colonic adenomas or an increased rate of colonic carcinoma when compared with Min mice with intact p53 This might suggest that this change may be associated with progression to cancer. In our study we noted that in the (p53 ϩ/ϩ ) (81). Reaves et al. (33) report in abstract form, that p53-deficient mice (p53 -/-) with chronic colitis induced by DALMs not all cells showed cytoplasmic/nuclear translocation (5-75%) of B-catenin. This phenomena has been noted in the DSS had significantly higher numbers of dysplastic lesions than control mice with chronic DSS colitis. Suzui et al. (34) human also (39, 40) .
The role of p53 in human colitis-associated neoplasia has reported a 0% incidence of p53 mutations in colitis-associated rat colon tumors induced solely by 1-hydroxyanthraquinone; been studied by both immunohistochemistry and molecular techniques. Immunohistochemical and molecular studies have however, they studied only three tumors. In our model we found that p53 mutations (as detected by immunohistochemistry) are reported that nuclear expression of p53 and both mutations and LOH of p53 occur as early events in human UC-related extremely uncommon in dysplasia and cancer in contrast to that seen in human UC-related neoplasia (23-24,27-29). Our neoplasia in contrast to colorectal neoplasia in the non- disease. We were unable to draw any conclusion regarding 
